SCHEMBL5743508

SCHEMBL5743508

CC(C)(C)OC(=O)N1CCC(CN)(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.48
CYP4A11 Q02928 1/20 0.48
USP2 O75604 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PKM P14618 1/20 0.40
HPGD P15428 1/20 0.40
EPHX2 P34913 1/20 0.40
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
RECQL P46063 1/20 0.38
EPHX1 P07099 1/20 0.38
DPP4 P27487 1/20 0.38
MMP2 P08253 2/20 0.38
MMP13 P45452 2/20 0.38
ADAM17 P78536 2/20 0.38
MMP14 P50281 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1958618 0.91 PKM (0.48) CYP4F2CYP4A11USP2SMN1; SMN2PKM
SCHEMBL4728853 0.91 CYP4F2 (0.52) CYP4F2CYP4A11USP2SMN1; SMN2PKM
SCHEMBL4728851 0.91 CYP4F2 (0.52) CYP4F2CYP4A11USP2SMN1; SMN2PKM
SCHEMBL390461 0.88 USP2 (0.42) CYP4F2CYP4A11USP2SMN1; SMN2PKM
SCHEMBL23527934 0.88 USP2 (0.46) CYP4F2CYP4A11USP2SMN1; SMN2PKM
SCHEMBL12691337 0.88 USP2 (0.46) CYP4F2CYP4A11USP2SMN1; SMN2PKM
SCHEMBL14155541 0.88 USP2 (0.46) CYP4F2CYP4A11USP2SMN1; SMN2HPGD
SCHEMBL2157135 0.86 USP2 (0.51) CYP4F2CYP4A11USP2SMN1; SMN2PKM
SCHEMBL18044818 0.83 CYP4F2 (0.43) CYP4F2CYP4A11
SCHEMBL18418212 0.82 USP2 (0.50) USP2SMN1; SMN2HPGDEPHX2OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109200-B2 Carbamate derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-09-19 US disclosed
EP-1340753-B1 CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2006-01-11 EP disclosed
US-20040038986-A1 Carbamate derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-02-26 US disclosed
US-6680312-B2 FOR THERAPY OF CARDIAC INFARCTION, CEREBRAL THROMBOSIS; INHIBIT ACTIVATED COAGULATION FACTOR X (FXA) TO SHOW ANTI-COAGULANT ACTIVITY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-01-20 US disclosed
EP-1340753-A1 CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-09-03 EP disclosed
US-20020193382-A1 Sulfonamide derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) 2002-12-19 US disclosed
US-6403595-B1 ANTICOAGULANTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-06-11 US disclosed
EP-1054005-A1 SULFONAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF Takeda Chemical Industries, Ltd. (JP) 2000-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038986-A1 Carbamate derivatives, process for producing the same and use thereof CFH, F11, F2 CYP4F2 91/4885CYP4A11 94/4885USP2 1088/4885
US-20020193382-A1 Sulfonamide derivatives, their production and use F12, F11, F2 CYP4F2 423/4885CYP4A11 572/4885USP2 3888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.